ZYBT Expands Into Pet Vaccine Market Postnasdaq IPO
Jilin Zhengye Biological Products Co., Ltd. has successfully listed on NASDAQ, becoming the first Chinese animal health company to IPO in the United States. The company plans to invest the raised capital primarily in the pet vaccine sector, including feline panleukopenia, calicivirus, and rhinotracheitis vaccines (feline 3-in-1 vaccine) and recombinant rabies glycoprotein, to meet market demand and enhance core competitiveness. With the booming domestic pet economy, the pet vaccine market has huge potential, and Zhengye Biology is expected to gain a favorable position in this field.
